George Tyler is a columnist for the Essex Reporter. A resident of Essex Junction, Tyler is a former journalist, village trustee and city councilor.
Vermont Senator Bernie Sanders has finally relented in holding up President Biden’s pick, Dr. Monica Bertagnolli, to head the National Institute of Health.
Sanders chairs the Senate’s Health, Education, Labor, and Pensions (HELP) Committee, which is the gatekeeper for presidential appointments to top positions in health care that are voted on by the full Senate, and he vowed earlier this year to use his position to hold up Biden’s recommended appointees as a way of pressuring the administration to do more to bring down prescription drug prices.
After refusing since May to schedule Bertagnolli to come before the committee, Sanders finally gave in and on Oct. 25 the committee voted 15-6 to recommend her to the full senate, with Sanders and five Republicans voting no. Sanders said he likes Bertagnolli and believes she’s qualified to head the government’s largest public funder of medical research, but unless she commits to using her authority at NIH to leverage drug makers to lower prices, he intends to continue voting against her appointment when she comes before the full Senate sometime later this year.
This is a mistake.
While it’s true that NIH funnels nearly $50 billion into medical research every year, it’s also true that this covers a wide range of loosely related research projects, most of which have little to do with drug development.
For example, NIH recently gave the University of Vermont $19.4 million to help improve biomedical education in Vermont’s four-year colleges and encourage more undergraduates to pursue careers in research. This is a great thing, for sure, but it’s a stretch to connect it with lower drug costs.
It’s true that the research NIH pays for in hundreds of academic institutions across the country produces a wealth of scientific knowledge that often leads to useful products. But it’s also true that turning a novel idea into a new drug or vaccine can cost hundreds of millions of private sector dollars.
For example, the basic concept of a vaccine that acts directly on the genetic machinery inside a person’s immune cells has been around since the 1980s and emerged from NIH funded research. But it required $2 billion in private venture capital and six years of focused research for the startup company Moderna to turn the idea into a safe and useable platform for vaccines like the Covid-19 vaccine.
When NIH moves beyond its basic research role and gets directly involved in drug development the benefits have been marginal.
A comprehensive study in the Journal of Therapeutic Innovation & Regulatory Science showed that for 18 drugs recently approved by the U.S. Food and Drug Administration, NIH contributed $670 million to the overall cost while the private sector contributed $44.3 billion. New drug development is hugely risky, and the study showed that when NIH got involved, their contribution to successful projects was so small, compared to the private sector’s, that the study authors half-seriously speculated about a negative correlation, i.e. the more NIH gets involved in developing a novel therapeutic idea, the less likely it is to succeed.
The bottom line is that the private sector pays most of the cost of new drug development but, as the study noted, many policy makers, journalists, and health care pundits still make the claim that NIH, i.e. “the government,” pays most of the bills while the private sector reaps the profits. This seems to be Sander’s argument, but the facts don’t support it.
Bertagnolli is an excellent choice for the job. Besides being a cancer surgeon, she’s published extensive research in the molecular biology of cancer and headed the surgical-oncology division at the Dana–Farber Cancer Institute in Boston. She’s well connected, highly regarded, and tuned in to the latest trends in medical science. If approved to head NIH, she would be only the second woman to hold the position.
During her lengthy hearing before Sander’s committee, some Republican members grilled her about spending public money on transgender health care and research that uses fetal tissue. Five of them apparently didn’t like her answers and voted against her. She’s likely to face similar resistance when she goes before the full Senate and, if approved, could find herself in the crosshairs of some new agenda-driven, factually-challenged crusade, as happened to Dr. Francis Collins, the former head of NIH, and Dr. Anthony Fauci, who headed NIH’s National Institute of Allergy and Infectious Diseases.
The House doesn’t vote on presidential appointments, but some Congressional Republicans have vowed to slash NIH’s budget.
Bertagnolli told Sanders' committee that one of her priorities would be restoring public trust in science. Given the rising anti-science, anti-institutional craziness in the country these days, she’s going to need all the help she can get, which is why she deserves Sander’s support.
Columns are opinion pieces regularly contributed by a select group of writers. Columns reflect the opinions of the writer and do not represent the views of the Essex Reporter.
Comments
No comments on this item Please log in to comment by clicking here